In this podcast, you will listen to Prof Antonis Kattamis summarizing the last developments in the treatment of patients with thalassemia. While the life expectancy of these patients has considerably improved in the last decades, quality of life and disease burden is still a relevant issue.
However, new classes of drugs, with action of the pathophysiologic mechanisms of the disease, are entering the clinics—drugs able to improve globin chain imbalance or ineffective erythropoiesis, or decrease hemolysis. Prof Kattamis will discuss the efficacy of these treatments and of innovative gene therapy approaches, not neglecting economic evaluations on the sustainability of new treatments in thalassemia.
Guest: Prof Antonis Kattamis
This podcast was recorded as a Spotlight Talks session during EHA2022. More podcasts from EHA2022 will be available in the future. Stay tuned!
View this podcast on EHA Campus for key slides related to this episode.
Learn More
If you liked this podcast and would like to explore related content, you can check out our EHA Thalassemia Program on the EHA Campus.
For more social media microlearning from EHA, visit https://ehaedu.org/SM_Learning.
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive EHA Educational Updates via https://eha.news/subscribe
You Might Like
